Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Disease 1

Interventions

Prednisone 3pembrolizumab 2Melphalan 2Cytarabine 2venetoclax 1ofatumumab 1obinutuzumab 1ioflupane 1imetelstat 1ibrutinib 1gossypol acetic acid 1gilteritinib 1fluorocholine 1fluciclovine F-18 1deltacortene 1daratumumab 1aflibercept 1abiraterone 1Temozolomide 1Self-Management 1Quality of Life 1Professional Autonomy 1Paclitaxel 1Oncolytic Virotherapy 1Octreotide 1Mitoxantrone 1Methylene Blue 1Lenalidomide 1Gemtuzumab 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Disease × Food × Clear all
NCT07299292 2025-12-23

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

SMED Clinical Research

Phase 2 Recruiting
60 enrolled
Genitourinary

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡